Day One Biopharmaceuticals lands $130m Series B

Day One Biopharmaceuticals, a provider of targeted therapies for children and adults with cancer, has raised $130 million in Series B financing.

Day One Biopharmaceuticals, a provider of targeted therapies for children and adults with cancer, has raised $130 million in Series B financing. RA Capital Management led the round.

Source: Press Release